Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

Artificial intelligence (AI) is providing several tools in revolutionising treatment options in neuro-oncology, especially in ...

Survey respondents preferred patient portal messages written by AI, but their satisfaction decreased when they were told that messages were written by AI.

Discover how gap cover can safeguard your financial future in retirement, addressing the rising healthcare costs faced by ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...

Breast cancer (malignant breast neoplasm) is a type of cancer originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk.

The median time to onset of myeloid neoplasm from ide-cel infusion was 338 days (Range: 277 to 794 days). Three of these five patients have died following the development of myeloid neoplasm.

Veteran firefighters appear to have a higher risk of brain tumors called gliomas, which can be caused by gene mutations ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Phyllodes tumors, varying from benign to malignant, need precise diagnosis and surgery, with a focus on multidisciplinary ...